Abstract
Poly(D,L-lactide-co-glycolide) (PLGA) polymers have been used for the production of biodegradable medical sutures and for controlled drug release for decades. Useful characteristics such as in vivo biodegradability, an adjustable release profile, and the very high encapsulation capacity have stimulated immunologists to explore PLGA microspheres (MS) as antigen delivery systems for vaccination for more than 15 yr. In previous studies aiming at the development of“single-dose” vaccines, direct immunization with PLGA MS containing various antigens induced strong and sustained immune responses. We have observed that human immature monocyte-derived dendritic cells (MoDC) prepared for clinical application are able to internalize high numbers of MS without negative effects on their pivotal properties. Furthermore, PLGA-MS-incorporated antigens are effectively processed for presentation on major histo-compatibility complex (MHC) class I and MHC class II molecules by dendritic cells (DCs) in vitro and induced strong cytotoxic T-lymphocyte (CTL) responses in vivo. Taken together, PLGA MS is a promising delivery vehicle for the improvement of current DC-based tumor vaccine protocols.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nestle, F. O., Alijagic, S., Gilliet, M., et al. (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4,328–332.
Thurner, B., Haendle, I., Roder, C., et al. (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669–1678.
Ludewig, B., McCoy, K., Pericin, M., et al. (2001) Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J. Immunol. 166, 3678–3687.
Thomasin, C., Corradin, G., Men, Y., Merkle, H. P., and Gander, B. (1996) Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) micro-spheres, importance of polymer degradation and antigen release for immune response. J. Control. Release 41,131–145.
Johansen, P., Men, Y., Merkle, H. P., and Gander, B. (2000) Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Bio-pharm. 50,129–146.
Men, Y., Audran, R., Thomasin, C., et al. (1999) MHC class I-and class II-restricted processing and presentation of microencapsulated antigens. Vaccine 17,1047–1056.
Walter, E., Dreher, D., Kok, M., et al. (2001) Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J. Control. Release 76,149–168.
Waeckerle-Men, Y., Scandella, E., Uetz-von Allmen, E., et al. (2004) Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J. Immunol. Meth. 287(1-2), 109–124.
Men, Y., Thomasin, C., Merkle, H., Gander, B., and Corradin, G. (1995) A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine 13, 683–689.
Men, Y., Gander, B., Merkle, H. P., and Corradin, G. (1996) Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 14, 1442–1450.
Men, Y., Tamber, H., Audran, R., Gander, B., and Corradin, G. (1997) Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Vaccine 15, 1405–1412.
Peter K., Men, Y., Pantaleo, G., Gander, B, and Corradin, G. (2001) Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. Vaccine 19, 4121–4129.
Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B., and Rock, K. L. (1993) Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.Proc. Natl. Acad. Sci. USA 90, 4942–4946.
Shen, Z., Reznikoff, G., Dranoff, G., and Rock, K. L. (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158, 2723–2730.
Ikuta, Y., Katayama, N., Wang, L. J., et al. (2002) Presentation of a major histocompat-ibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 99, 3717–3724.
Audran, R., Peter, K., Dannull, J., et al. (2003) Micro-encapsulation of peptides prolongs their presentation to cytotoxic T cells by antigen presenting cells in vitro. Vaccine 21, 1250–1255.
Sah, H. 1997. A new strategy to determine the actual protein content of poly(lactide-co-glycolide) microspheres. J. Pharm. Sci. 86, 1315–1318.
Scandella, E., Men, Y., Gillessen, S., Förster, R., and Groettrup, M. (2002) Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100, 1354–1361.
Panyam, J., Zhou, W. Z., Prabha, S., Sahoo, S. K., and Labhasetwar, V. (2002) Rapidendo-lysosomal escape of poly(D,L-lactide-co-glycolide) nanoparticles: implications fordrug and gene delivery. FASEB J. 16, 1217–1226.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Waeckerle-Men, Y., Gander, B., Groettrup, M. (2005). Delivery of Tumor Antigens to Dendritic Cells Using Biodegradable Microspheres. In: Ludewig, B., Hoffmann, M.W. (eds) Adoptive Immunotherapy: Methods and Protocols. Methods in Molecular Medicine™, vol 109. Humana Press. https://doi.org/10.1385/1-59259-862-5:035
Download citation
DOI: https://doi.org/10.1385/1-59259-862-5:035
Publisher Name: Humana Press
Print ISBN: 978-1-58829-406-7
Online ISBN: 978-1-59259-862-5
eBook Packages: Springer Protocols